The role of endoscopic treatment of vesicoureteral reflux

A 17-year experience

Nicola Capozza, Alberto Lais, Simona Nappo, Paolo Caione, H. Gil Rushton

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Purpose: During the last 20 years endoscopic treatment of vesicoureteral reflux (VUR) has gained popularity in European countries. We performed a retrospective analysis of our 17-year experience with more than 1,000 patients treated to assess whether technique, indications or results of endoscopic treatment of VUR have changed over time. Materials and Methods: From January 1986 to June 2002, 1,244 patients underwent endoscopic treatment for grades II to IV VUR. Polytetrafluoroethylene was injected as the bulking material in the first 14 cases, after 1989 bovine cross-linked collagen was used in 442 and since 1995 dextranomer/hyaluronic acid copolymer was used in 788. Urinary tract ultrasound was performed 1 and 6 months, and micturition cystourethrogram was done 3 and 12 months after endoscopic treatment. All patients included in the study completed a minimum 12-month followup. Results: Endoscopic treatment was always performed in 1 day. Complications were observed in 0.5% of cases. After 1 or 2 injections the micturition cystourethrogram showed no significant VUR (absent or grade I) in 77% of cases. The success rate was 88%, 75% and 52% for grades II, III and IV VUR, respectively. With increasing experience not only primary VUR, but also secondary reflux was considered eligible for endoscopic treatment, and the number of grade IV VUR cases treated by endoscopy also increased. The presence of voiding dysfunction was identified as a limiting factor in the success of endoscopic treatment. Conclusions: The short hospital stay, acceptable success rate and absence of significant complications prompt us to consider endoscopic treatment as first choice treatment of VUR rather than long-term prophylaxis and open surgery. Even grade IV VUR and VUR in complex anatomical situations can be successfully treated by endoscopy. Patients with voiding dysfunction should be identified and adequately treated before any endoscopic attempt.

Original languageEnglish
Pages (from-to)1626-1629
Number of pages4
JournalJournal of Urology
Volume172
Issue number4 II
DOIs
Publication statusPublished - Oct 2004

Fingerprint

A 17
Vesico-Ureteral Reflux
Therapeutics
Urination
Endoscopy
Polytetrafluoroethylene
Urinary Tract
Length of Stay
Collagen

Keywords

  • Collagen
  • Endoscopy
  • Hyaluronic acid
  • Vesico-ureteral reflux

ASJC Scopus subject areas

  • Urology

Cite this

The role of endoscopic treatment of vesicoureteral reflux : A 17-year experience. / Capozza, Nicola; Lais, Alberto; Nappo, Simona; Caione, Paolo; Rushton, H. Gil.

In: Journal of Urology, Vol. 172, No. 4 II, 10.2004, p. 1626-1629.

Research output: Contribution to journalArticle

@article{77d3f1da8955418581c3edafcf3f0271,
title = "The role of endoscopic treatment of vesicoureteral reflux: A 17-year experience",
abstract = "Purpose: During the last 20 years endoscopic treatment of vesicoureteral reflux (VUR) has gained popularity in European countries. We performed a retrospective analysis of our 17-year experience with more than 1,000 patients treated to assess whether technique, indications or results of endoscopic treatment of VUR have changed over time. Materials and Methods: From January 1986 to June 2002, 1,244 patients underwent endoscopic treatment for grades II to IV VUR. Polytetrafluoroethylene was injected as the bulking material in the first 14 cases, after 1989 bovine cross-linked collagen was used in 442 and since 1995 dextranomer/hyaluronic acid copolymer was used in 788. Urinary tract ultrasound was performed 1 and 6 months, and micturition cystourethrogram was done 3 and 12 months after endoscopic treatment. All patients included in the study completed a minimum 12-month followup. Results: Endoscopic treatment was always performed in 1 day. Complications were observed in 0.5{\%} of cases. After 1 or 2 injections the micturition cystourethrogram showed no significant VUR (absent or grade I) in 77{\%} of cases. The success rate was 88{\%}, 75{\%} and 52{\%} for grades II, III and IV VUR, respectively. With increasing experience not only primary VUR, but also secondary reflux was considered eligible for endoscopic treatment, and the number of grade IV VUR cases treated by endoscopy also increased. The presence of voiding dysfunction was identified as a limiting factor in the success of endoscopic treatment. Conclusions: The short hospital stay, acceptable success rate and absence of significant complications prompt us to consider endoscopic treatment as first choice treatment of VUR rather than long-term prophylaxis and open surgery. Even grade IV VUR and VUR in complex anatomical situations can be successfully treated by endoscopy. Patients with voiding dysfunction should be identified and adequately treated before any endoscopic attempt.",
keywords = "Collagen, Endoscopy, Hyaluronic acid, Vesico-ureteral reflux",
author = "Nicola Capozza and Alberto Lais and Simona Nappo and Paolo Caione and Rushton, {H. Gil}",
year = "2004",
month = "10",
doi = "10.1097/01.ju.0000138381.75175.b9",
language = "English",
volume = "172",
pages = "1626--1629",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4 II",

}

TY - JOUR

T1 - The role of endoscopic treatment of vesicoureteral reflux

T2 - A 17-year experience

AU - Capozza, Nicola

AU - Lais, Alberto

AU - Nappo, Simona

AU - Caione, Paolo

AU - Rushton, H. Gil

PY - 2004/10

Y1 - 2004/10

N2 - Purpose: During the last 20 years endoscopic treatment of vesicoureteral reflux (VUR) has gained popularity in European countries. We performed a retrospective analysis of our 17-year experience with more than 1,000 patients treated to assess whether technique, indications or results of endoscopic treatment of VUR have changed over time. Materials and Methods: From January 1986 to June 2002, 1,244 patients underwent endoscopic treatment for grades II to IV VUR. Polytetrafluoroethylene was injected as the bulking material in the first 14 cases, after 1989 bovine cross-linked collagen was used in 442 and since 1995 dextranomer/hyaluronic acid copolymer was used in 788. Urinary tract ultrasound was performed 1 and 6 months, and micturition cystourethrogram was done 3 and 12 months after endoscopic treatment. All patients included in the study completed a minimum 12-month followup. Results: Endoscopic treatment was always performed in 1 day. Complications were observed in 0.5% of cases. After 1 or 2 injections the micturition cystourethrogram showed no significant VUR (absent or grade I) in 77% of cases. The success rate was 88%, 75% and 52% for grades II, III and IV VUR, respectively. With increasing experience not only primary VUR, but also secondary reflux was considered eligible for endoscopic treatment, and the number of grade IV VUR cases treated by endoscopy also increased. The presence of voiding dysfunction was identified as a limiting factor in the success of endoscopic treatment. Conclusions: The short hospital stay, acceptable success rate and absence of significant complications prompt us to consider endoscopic treatment as first choice treatment of VUR rather than long-term prophylaxis and open surgery. Even grade IV VUR and VUR in complex anatomical situations can be successfully treated by endoscopy. Patients with voiding dysfunction should be identified and adequately treated before any endoscopic attempt.

AB - Purpose: During the last 20 years endoscopic treatment of vesicoureteral reflux (VUR) has gained popularity in European countries. We performed a retrospective analysis of our 17-year experience with more than 1,000 patients treated to assess whether technique, indications or results of endoscopic treatment of VUR have changed over time. Materials and Methods: From January 1986 to June 2002, 1,244 patients underwent endoscopic treatment for grades II to IV VUR. Polytetrafluoroethylene was injected as the bulking material in the first 14 cases, after 1989 bovine cross-linked collagen was used in 442 and since 1995 dextranomer/hyaluronic acid copolymer was used in 788. Urinary tract ultrasound was performed 1 and 6 months, and micturition cystourethrogram was done 3 and 12 months after endoscopic treatment. All patients included in the study completed a minimum 12-month followup. Results: Endoscopic treatment was always performed in 1 day. Complications were observed in 0.5% of cases. After 1 or 2 injections the micturition cystourethrogram showed no significant VUR (absent or grade I) in 77% of cases. The success rate was 88%, 75% and 52% for grades II, III and IV VUR, respectively. With increasing experience not only primary VUR, but also secondary reflux was considered eligible for endoscopic treatment, and the number of grade IV VUR cases treated by endoscopy also increased. The presence of voiding dysfunction was identified as a limiting factor in the success of endoscopic treatment. Conclusions: The short hospital stay, acceptable success rate and absence of significant complications prompt us to consider endoscopic treatment as first choice treatment of VUR rather than long-term prophylaxis and open surgery. Even grade IV VUR and VUR in complex anatomical situations can be successfully treated by endoscopy. Patients with voiding dysfunction should be identified and adequately treated before any endoscopic attempt.

KW - Collagen

KW - Endoscopy

KW - Hyaluronic acid

KW - Vesico-ureteral reflux

UR - http://www.scopus.com/inward/record.url?scp=4544361303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544361303&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000138381.75175.b9

DO - 10.1097/01.ju.0000138381.75175.b9

M3 - Article

VL - 172

SP - 1626

EP - 1629

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4 II

ER -